Minulet (Ethinylestradiol, Gestodene)

The ethinylestradiol component suppresses follicle‑stimulating hormone, while gestodene blocks the luteinizing hormone surge, together preventing ovulation. In addition, gestodene thickens cervical mucus and alters the endometrial lining, making it difficult for sperm to reach an egg and for a fertilized egg to implant.

The dosing regimen for Minulet is determined by the prescribing healthcare professional. Typically, combined oral contraceptives are taken once daily, but the exact schedule, number of tablets per pack and any hormone‑free interval are set by the prescriber based on individual patient needs.

Minulet is contraindicated during pregnancy and should be stopped if pregnancy is confirmed. Limited data exist for use while breastfeeding; however, most guidelines advise caution and recommend discussing alternatives with a healthcare provider before using hormonal contraception during lactation.

To order Minulet, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Minulet contains gestodene, a third‑generation progestogen, which is associated with a lower incidence of androgenic side effects such as acne compared with older progestins. Its estrogen component, ethinylestradiol, is at a standard dose for combined pills, offering efficacy comparable to other EU‑approved contraceptive tablets.

Minulet tablets should be stored at ambient temperature, preferably below 25 °C, in their original blister pack to protect from moisture and light. Keep the product out of reach of children and avoid storing in bathrooms or other humid environments.

Minulet is taken orally, usually as a single tablet each day at the same time. The prescriber will define the number of consecutive days the tablet is taken and any hormone‑free interval, which is typically followed by a short break before starting the next pack.

The most serious risks include venous or arterial thromboembolism, such as deep‑vein thrombosis, pulmonary embolism, stroke, or myocardial infarction. Other critical concerns are severe hypertension, liver disorders, and rare allergic reactions. Patients should seek immediate medical attention if they experience sudden chest pain, shortness of breath, severe headache, visual changes, or unexplained swelling of the limbs.

Minulet is contraindicated in women with a history of thromboembolic disorders, uncontrolled hypertension, active liver disease, known or suspected breast or endometrial cancer, and those who are pregnant or breastfeeding without medical advice. It should also be avoided in smokers over 35 years of age and in individuals taking strong enzyme‑inducing medications that reduce contraceptive efficacy.